These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8616095)

  • 1. Physiologic concentrations of arginine vasopressin activate human platelets in vitro.
    Wun T; Paglieroni T; Lachant NA
    Br J Haematol; 1996 Mar; 92(4):968-72. PubMed ID: 8616095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desmopressin stimulates the expression of P-selectin on human platelets in vitro.
    Wun T; Paglieroni TG; Lachant NA
    J Lab Clin Med; 1995 Oct; 126(4):401-9. PubMed ID: 7561450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of human platelet vasopressin receptor and the relation between vasopressin-induced platelet aggregation and vasopressin binding to platelets.
    Inaba K; Umeda Y; Yamane Y; Urakami M; Inada M
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):377-86. PubMed ID: 2978018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors.
    Musabayane CT; Forsling ML; Balment RJ
    Ren Fail; 1997 Jan; 19(1):23-32. PubMed ID: 9044449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginine vasopressin enhances sympathetic constriction through the V1 vasopressin receptor in human saphenous vein.
    Medina P; Acuña A; Martínez-León JB; Otero E; Vila JM; Aldasoro M; Lluch S
    Circulation; 1998 Mar; 97(9):865-70. PubMed ID: 9580082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system.
    Croiset G; De Wied D
    Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro effects of arginine-vasopressin receptor antagonists on the hypothalamic-pituitary-adrenal axis in the rat.
    Bernardini R; Chiarenza A; Kamilaris TC; Renaud N; Lempereur L; Demitrack M; Gold PW; Chrousos GP
    Neuroendocrinology; 1994 Nov; 60(5):503-8. PubMed ID: 7845540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine vasopressin stimulates proliferation of adult rat cardiac fibroblasts via protein kinase C-extracellular signal-regulated kinase 1/2 pathway.
    He YP; Zhao LY; Zheng QS; Liu SW; Zhao XY; Lu XL; Niu XL
    Sheng Li Xue Bao; 2008 Jun; 60(3):333-40. PubMed ID: 18560723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of vasopressin-induced platelet aggregation.
    Filep J; Rosenkranz B
    Thromb Res; 1987 Jan; 45(1):7-15. PubMed ID: 3105115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of arginine vasopressin actions in human uterine artery: lack of role of the vascular endothelium.
    Jovanović A; Grbović L; Zikić I; Tulic I
    Br J Pharmacol; 1995 Aug; 115(7):1295-301. PubMed ID: 7582559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors.
    Lee B; Yang C; Chen TH; al-Azawi N; Hsu WH
    Am J Physiol; 1995 Dec; 269(6 Pt 1):E1095-100. PubMed ID: 8572202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors.
    Yibchok-anun S; Hsu WH
    Life Sci; 1998; 63(21):1871-8. PubMed ID: 9825765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin acts on platelets to generate procoagulant activity.
    Tomasiak M; Stelmach H; Rusak T; Ciborowski M; Radziwon P
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):615-24. PubMed ID: 18832900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
    Ferris CF; Singer EA; Meenan DM; Albers HE
    Eur J Pharmacol; 1988 Sep; 154(2):153-9. PubMed ID: 2976377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin-induced calcium signaling in cultured hippocampal neurons.
    Brinton RD; Gonzalez TM; Cheung WS
    Brain Res; 1994 Oct; 661(1-2):274-82. PubMed ID: 7834378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor.
    Graff J; Klinkhardt U; Schini-Kerth VB; Harder S; Franz N; Bassus S; Kirchmaier CM
    J Pharmacol Exp Ther; 2002 Mar; 300(3):952-7. PubMed ID: 11861803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists.
    Ohlstein EH; Berkowitz BA
    J Pharmacol Exp Ther; 1986 Dec; 239(3):737-41. PubMed ID: 2948008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes.
    Torres BA; Johnson HM
    J Immunol; 1988 Apr; 140(7):2179-83. PubMed ID: 2965181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.